NICE approves adalimumab for psoriasis

NICE has published guidance on the use of adalimumab (Humira), an anti-TNF agent for the treatment of psoriasis.

It recommends adalimumab as a treatment option for adults with plaque psoriasis for whom anti-TNF treatment is being considered and when both of the following criteria are fulfilled:

  • The disease is severe (defined as a Psoriasis Area Sensitivity Index [PASI] and a Dermatology Life Quality Index [DLQI] of more than 10).
  • The disease has not responded to previous therapies including ciclosporin, methotrexate and PUVA, or the patient is intolerant or has a contraindication to these treatments.
  • Adalimumab should be discontinued in patients whose psoriasis has not responded adequately at 16 weeks.

Read the full NICE guidance

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more